pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$LPCNLipocine Inc.

$LPCN
Salt Lake City, USupdated 21d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
5
marketed
2
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(5)

pipeline depth5 products
Phase 1: 1Phase 2: 2Marketed: 2
1Phase 12Phase 22Marketed
Marketed
LPCN-1144
Metabolic Dysfunction-Associated Steatohepatitis (MASH or…
Androgen receptor
Marketed
brexanolone
Post Partum Depression (Maternal Depression / Postnatal D…
GABA-A receptor; anion channel
Phase 2
hydroxyprogesterone caproate
Premature Labor (Tocolysis)
Phase 2
testosterone tridecanoate
Sarcopenia
Phase 1
eltanolone
Epilepsy

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPDcompletedn=90
  • phase2A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trialcompletedn=25
  • phase2A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopeniacompletedn=30
  • phase2The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitiscompletedn=56

Insider activity

source: SEC Form 4

open-market buys + sells

  • Apr 7, 26BUYHiguchi John W.· 40,000 sh @ $2.03$81K↗
  • Apr 6, 26BUYHiguchi John W.· 123,000 sh @ $2.05$252K↗
  • Apr 6, 26BUYPatel Mahesh V.· Chief Executive Officer25,000 sh @ $2.03$51K↗
  • Apr 2, 26BUYPatel Mahesh V.· Chief Executive Officer25,000 sh @ $2.02$51K↗
🐶 Hiring Signal
No open roles indexed yet — view Lipocine Inc. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$LPCN
SEC CIK
0001535955
country
US
source
sec_tickers
top tags
Women's Health2Alzheimer's Disease1Epilepsy1Oncology1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 4m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?